

Karl Philip Claxton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8139725/publications.pdf>

Version: 2024-02-01

69
papers

6,673
citations

147801

31
h-index

106344

65
g-index

70
all docs

70
docs citations

70
times ranked

7412
citing authors

#	ARTICLE	IF	CITATIONS
1	Reference Case Methods for Expert Elicitation in Health Care Decision Making. <i>Medical Decision Making</i> , 2022, 42, 182-193.	2.4	12
2	Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. <i>Health Policy and Planning</i> , 2022, 37, 45-54.	2.7	8
3	How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 557-572.	2.1	5
4	Valuing health outcomes: developing better defaults based on health opportunity costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 729-736.	1.4	16
5	Authors'™ Response to: "Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al." by Sampson, Firth, and Towse. <i>Medical Decision Making</i> , 2021, 41, 258-260.	2.4	3
6	Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study. <i>Health Technology Assessment</i> , 2021, 25, 1-124.	2.8	29
7	Does public long-term care expenditure improve care-related quality of life of service users in England?. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2561-2581.	1.7	5
8	How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 885-903.	2.1	16
9	Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2649-2666.	1.7	8
10	Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014. <i>BMJ Open</i> , 2021, 11, e046417.	1.9	11
11	Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi. <i>BMJ Global Health</i> , 2021, 6, e007047.	4.7	1
12	Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. <i>BMJ Global Health</i> , 2020, 5, e003006.	4.7	14
13	Practical metrics for establishing the health benefits of research to support research prioritisation. <i>BMJ Global Health</i> , 2020, 5, e002152.	4.7	3
14	Estimating Social Variation in the Health Effects of Changes in Health Care Expenditure. <i>Medical Decision Making</i> , 2020, 40, 170-182.	2.4	17
15	Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. <i>BMJ Open</i> , 2020, 10, e036411.	1.9	28
16	Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts. <i>Medical Decision Making</i> , 2020, 40, 448-459.	2.4	18
17	Value-based tiered pricing for universal health coverage: an idea worth revisiting. <i>Gates Open Research</i> , 2020, 4, 16.	1.1	9
18	The epidemiology, management and impact of surgical wounds healing by secondary intention: a research programme including the SWHSI feasibility RCT. <i>Programme Grants for Applied Research</i> , 2020, 8, 1-122.	1.0	0

#	ARTICLE	IF	CITATIONS
19	What next after GDP-based cost-effectiveness thresholds?. Gates Open Research, 2020, 4, 176.	1.1	36
20	Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. Value in Health, 2019, 22, 995-1002.	0.3	45
21	The Value of Further Research: The Added Value of Individual-Participant Level Data. Applied Health Economics and Health Policy, 2019, 17, 273-284.	2.1	3
22	Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 10, 73-105.	1.2	17
23	The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics (United Kingdom) 40(10):1471-1494. doi:10.1017/S0263442219000107	1.7	10
24	Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. Value in Health, 2018, 21, 266-275.	0.3	58
25	Supporting the development of a health benefits package in Malawi. BMJ Global Health, 2018, 3, e000607.	4.7	42
26	Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system. Health Economics (United Kingdom), 2018, 27, e28-e40.	1.7	2
27	How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework. Health Economics (United Kingdom), 2018, 27, e41-e54.	1.7	5
28	A Cost-Effectiveness Analysis of Intradiscal Electrothermal Therapy Compared with Circumferential Lumbar Fusion. Pain Practice, 2018, 18, 515-522.	1.9	4
29	Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health, 2018, 3, e000964.	4.7	181
30	Appraising the value of evidence generation activities: an HIV modelling study. BMJ Global Health, 2018, 3, e000488.	4.7	7
31	Comment: Positive tails and normative dogs. Health Economics (United Kingdom), 2018, 27, 1425-1427.	1.7	0
32	Discounting in Economic Evaluations. Pharmacoeconomics, 2018, 36, 745-758.	3.3	210
33	Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses. Value in Health, 2018, 21, 715-723.	0.3	31
34	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. Health Economics (United Kingdom), 2017, 26, 109-123.	1.7	52
35	Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions. Value in Health, 2017, 20, 234-239.	0.3	64
36	Cancer Drugs Fund requires further reform. BMJ, The, 2016, 354, i5090.	6.0	26

#	ARTICLE	IF	CITATIONS
37	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. <i>Value in Health</i> , 2016, 19, 921-928.	0.3	203
38	Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. <i>Value in Health</i> , 2016, 19, 929-935.	0.3	589
39	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. <i>Health Economics (United Kingdom)</i> , 2016, 25, 933-938.	1.7	23
40	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. <i>Value in Health</i> , 2016, 19, 885-891.	0.3	38
41	Methods to place a value on additional evidence are illustrated using a case study of corticosteroids after traumatic brain injury. <i>Journal of Clinical Epidemiology</i> , 2016, 70, 183-190.	5.0	4
42	Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. <i>Value in Health</i> , 2015, 18, 865-875.	0.3	17
43	CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?. <i>Health Economics (United Kingdom)</i> , 2015, 24, 1-7.	1.7	88
44	How to estimate the health benefits of additional research and changing clinical practice. <i>BMJ</i> , The, 2015, 351, h5987.	6.0	21
45	Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. <i>Health Technology Assessment</i> , 2015, 19, 1-504.	2.8	536
46	The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis. <i>Medical Decision Making</i> , 2014, 34, 951-964.	2.4	67
47	Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse. <i>Medical Decision Making</i> , 2013, 33, 415-436.	2.4	32
48	Budget allocation and the revealed social rate of time preference for health. <i>Health Economics (United Kingdom)</i> , 2012, 21, 612-618.	1.7	32
49	A Framework for Addressing Structural Uncertainty in Decision Models. <i>Medical Decision Making</i> , 2011, 31, 662-674.	2.4	72
50	Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration. <i>Statistics in Medicine</i> , 2011, 30, 2363-2380.	1.6	47
51	Discounting and decision making in the economic evaluation of health-care technologies. <i>Health Economics (United Kingdom)</i> , 2011, 20, 2-15.	1.7	156
52	Addressing Adoption and Research Design Decisions Simultaneously. <i>Medical Decision Making</i> , 2011, 31, 853-865.	2.4	52
53	Eliciting Distributions to Populate Decision Analytic Models. <i>Value in Health</i> , 2010, 13, 557-564.	0.3	47
54	Exploring Uncertainty in Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2008, 26, 781-798.	3.3	156

#	ARTICLE	IF	CITATIONS
55	Linee guida di buona pratica per creare modelli analitico-decisionali nella valutazione delle tecnologie sanitarie. <i>Giornale Italiano Di Health Technology Assessment</i> , 2008, 1, 1-14.	0.1	0
56	Value based pricing for NHS drugs: an opportunity not to be missed?. <i>BMJ: British Medical Journal</i> , 2008, 336, 251-254.	2.3	178
57	The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions?. <i>Medical Decision Making</i> , 2008, 28, 287-299.	2.4	60
58	Rights, responsibilities and NICE: a rejoinder to Harris. <i>Journal of Medical Ethics</i> , 2007, 33, 462-464.	1.8	15
59	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. <i>Journal of Health Services Research and Policy</i> , 2007, 12, 56-58.	1.7	155
60	OFT, VBP: QED?. <i>Health Economics (United Kingdom)</i> , 2007, 16, 545-558.	1.7	102
61	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. <i>Health Economics (United Kingdom)</i> , 2005, 14, 339-347.	1.7	368
62	A rational framework for decision making by the National Institute For Clinical Excellence (NICE). <i>Lancet, The</i> , 2002, 360, 711-715.	13.7	378
63	Representing uncertainty: the role of cost-effectiveness acceptability curves. <i>Health Economics (United Kingdom)</i> , 2001, 10, 779-787.	1.7	885
64	Assessing Quality in Decision Analytic Cost-Effectiveness Models. <i>Pharmacoeconomics</i> , 2000, 17, 461-477.	3.3	172
65	Redefining the analytical approach to pharmacoeconomics. , 1999, 8, 187-189.		15
66	Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. <i>Health Economics (United Kingdom)</i> , 1999, 8, 269-274.	1.7	112
67	The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. <i>Journal of Health Economics</i> , 1999, 18, 341-364.	2.7	725
68	Redefining the analytical approach to pharmacoeconomics. <i>Health Economics (United Kingdom)</i> , 1999, 8, 187-189.	1.7	2
69	An economic approach to clinical trial design and research priority-setting. <i>Health Economics (United)</i> Tj ETQq1 1 0,784314 rgBT /Overld 1.7 816	1.7	816